Page 2 - Evaluate Safety News Today

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and...

On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman LitigationOn March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and...

In this guide, we'll provide a step-by-step approach to help you navigate the decision-making process.

MORRISVILLE, N.C., Jan. 25, 2024 -- Liquidia Corporation announced today that the U.S. Food and Drug Administration provided an update on its review of the New Drug Application for YUTREPIA™ ...

SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical-stage innovative biopharmaceutical company, announced recently that the

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,...

The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.

/PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) today announced the European Commission has approved TAKHZYRO® (lanadelumab) for the routine prevention of recurrent...

- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age...

- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six.